AR048315A1 - Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. - Google Patents
Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.Info
- Publication number
- AR048315A1 AR048315A1 ARP050100899A ARP050100899A AR048315A1 AR 048315 A1 AR048315 A1 AR 048315A1 AR P050100899 A ARP050100899 A AR P050100899A AR P050100899 A ARP050100899 A AR P050100899A AR 048315 A1 AR048315 A1 AR 048315A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally
- alkoxy
- substituted
- cr7r8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
Abstract
Compuestos descriptos de la formula (1), que inhiben la produccion de citocinas implicadas en procesos inflamatorios y que, por lo tanto, son utiles para tratar enfermedades y afecciones patologicas que implican inflamacion, como la enfermedad inflamatoria cronica. También se describen composiciones farmacéuticas que comprenden estos compuestos utilizables para el tratamiento de enfermedades oncologicas además de las ya mencionadas. Reivindicacion 1: Un compuesto de la formula (1), en el que: Ar1 se selecciona entre i), ii) y iii) a continuacion: i) un carbociclo sustituido con R1, R2 y Rx; ii) una formula (2), en el que uno de E o F es nitrogeno y el otro es carbono, R1 está covalentemente unido o bien a E o F y, cuando nitrogeno es N-R1, no está presente el enlace doble entre E y F; iii) una formula (3) en el que c es un anillo benzo condensado al anillo d que es un anillo heterocíclico de 5-7 miembros opcionalmente sustituido con un grupo oxo (=O), y uno a dos grupos R, siendo cada uno independientemente H o alquilo C1-3; R1 se selecciona entre hidrogeno, NO2, -N(Rc)2, J-C(O)-N(Rc)-, J-S(O)m-N(Rc)-, alquiloC1-6S(O)m-; o R1 se selecciona entre alquilo C1-6, cicloalquilo C3-7, alcoxilo C1-5 o cicloalcoxilo C3-7, alquiltiol C1-5 o cicicloalquiltiol C3-7, acilo C1-5, alcoxicarbonilo C1-5, aciloxi C1-5, acilamino C1-5, alquenilo C2-5, alquinilo C2-5, heterociclo, heterocicloalquilo C1-6, heteroarilo, heteroarilalquilo C1-6 y nitrilo; cada uno de los anteriormente mencionados, cuando es posible, está opcionalmente parcial o totalmente halogenado o está opcionalmente sustituido además con alquilsulfonilamino, aminocarboxilo, alcoxilo, amino, alquilamino, dialquilamino, hidroxilo, oxo, nitro o nitrilo; R2 se selecciona entre: hidrogeno, halogeno, nitrilo, alquiloC1-5S(O)m-, ariloS(O)m, J-O-C(O)-O-, N(Rc)2-C(O)-(CH2)n-, acetilo C1-6, aroilo, alcoxicarbonilo C1-6, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, cicloalcoxi C3-5, alquilo C1- 5alcoxiC1-5, hidroxi, hidroxialquilo C1-5 y amino opcionalmente mono o di-sustituido C1-5, arilo o arilalquilo C1-5; cada uno de los ya mencionados, cuando es posible, está opcionalmente parcial o totalmente halogenado u opcionalmente también sustituido con alquilo C1-3, alquilsulfonilamino, alcoxilo, amino, alquilamino, dialquilamino, hidroxilo, oxo, nitro o nitrilo; cada Rx se selecciona entre alquilo C1-6 o cicloalquilo C3-7, estando cada uno opcionalmente sustituido con alquilo C1-3 y opcionalmente parcial o totalmente halogenado, acilo C1-4, aroilo, alcoxi C1-4, alquiloC1-5S(O)m-, en los que cada uno puede estar opcionalmente parcial o totalmente halogenado, halogeno, alcoxicarbonilo C1-6, carbociclosulfonilo; cada Rc es indepedientemente hidrogeno o alquilo C1-5; D, A y B del resto de formula (4) de la formula (1) se seleccionan cada uno independientemente entre N o CH, en los que el átomo de hidrogeno está opcionalmente reemplazado con R6; Het es un anillo de heteroarilo o heterocíclico, en el que Het está opcionalmente sustituido con uno a tres R5; m es 0, 1 o 2; J se selecciona entre alquilo C1-10 y cicloalquilo C3-7, cada uno opcionalmente sustituido con Rb; R3, R4, R6, R7 y R8 se seleccionan cada uno independientemente entre hidrogeno, halogeno, alquilo C1-5, alcoxi C1-5, alquiloC1-5alcoxiC1-5, hidroxi, hidroxialquilo C1-5 o amino opcionalmente mono o di-sustituido con alquilo C1-5, arilo o arilalquilo C1-5; R5 es: Ra, -O-Ra, -S(O)m-Ra, -N(Ra)2, -C(O)-Ra, -NH(CR7R8)n-Ra, N(Ra)2-(CH2)1-2-, -(CR7R8)n-Ra, -O(CR7R8)n-Ra, -C(O)-O(CR7R8)n-Ra, -C(O)(CR7R8)n-Ra, -C(O)C(O)Ra, -C(O)C(O)ORa, -C(O)NHRa o -C(O)NH(CR7R8)n-, cada uno opcionalmente sustituido con alquilo C1-3, halogeno o hidroxi; en los que n es 1-5; o R5 es arilo, heteroarilo o heterociclilo, cada uno opcionalmente sustituido con Ra; Ra y Rb se seleccionan cada uno independientemente entre hidrogeno, alquilo C1-6, hidroxialquilo C1-5, alquenilo C2-5, alquinilo C2-5, carbociclo, carbocicloalquilo C0-2, arilo, heterociclo, heteroarilo, alcoxi C1-5, alquiltio C1-5, amino, alquilamino C1-5, dialquilamino C1-5, arilamino, arilalquilamino C1-5, diarilamino, acilo C1-5, alcoxicarbonilo C1-5, aciloxi C1-5, acilamino C1-5, en los que cada uno de los ya mencionados está opcionalmente parcial o totalmente halogenado, o Ra y Rb se seleccionan entre alquilsulfonilamino C1-5, hidroxi, oxo, halogeno, CF3, -CH2-CF3, nitro y nitrilo, en los que cada carbociclo, heterociclo o heteroarilo C1-3, halogeno o hidroxi; y X es O o S; o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55144504P | 2004-03-09 | 2004-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048315A1 true AR048315A1 (es) | 2006-04-19 |
Family
ID=34962594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100899A Pending AR048315A1 (es) | 2004-03-09 | 2005-03-09 | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. |
Country Status (30)
Country | Link |
---|---|
US (2) | US7214802B2 (es) |
EP (2) | EP1725544B1 (es) |
JP (1) | JP4850824B2 (es) |
KR (1) | KR20060129077A (es) |
CN (1) | CN1930144A (es) |
AR (1) | AR048315A1 (es) |
AT (1) | ATE432273T1 (es) |
AU (1) | AU2005223738B2 (es) |
BR (1) | BRPI0508561A (es) |
CA (1) | CA2557856C (es) |
CY (1) | CY1109333T1 (es) |
DE (1) | DE602005014621D1 (es) |
DK (1) | DK1725544T3 (es) |
EA (1) | EA011634B1 (es) |
EC (1) | ECSP066833A (es) |
ES (1) | ES2327940T3 (es) |
HR (1) | HRP20090334T1 (es) |
IL (1) | IL177937A0 (es) |
MY (1) | MY143000A (es) |
NO (1) | NO20064120L (es) |
NZ (1) | NZ550148A (es) |
PE (1) | PE20051146A1 (es) |
PL (1) | PL1725544T3 (es) |
PT (1) | PT1725544E (es) |
RS (1) | RS50796B (es) |
SI (1) | SI1725544T1 (es) |
TW (1) | TW200602313A (es) |
UA (1) | UA85702C2 (es) |
WO (1) | WO2005090333A1 (es) |
ZA (1) | ZA200606177B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536618A (ja) * | 2006-04-18 | 2009-10-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4−及び5−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体 |
EA200900072A1 (ru) * | 2006-07-07 | 2009-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств |
CN101511796B (zh) | 2006-09-05 | 2012-05-09 | 协和发酵麒麟株式会社 | 咪唑衍生物 |
PE20090837A1 (es) * | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
JP2010531850A (ja) * | 2007-07-02 | 2010-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
WO2009070304A1 (en) | 2007-11-27 | 2009-06-04 | North Carolina State University | Inhibition of biofilms in plants with imidazole derivatives |
WO2009123753A1 (en) | 2008-04-04 | 2009-10-08 | North Carolina State University | Inhibition of bacterial biofilms with imidazole-phenyl derivatives |
US7897631B2 (en) * | 2008-04-21 | 2011-03-01 | North Carolina State University | Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives |
JP2012501317A (ja) * | 2008-09-02 | 2012-01-19 | ノイロサーチ アクティーゼルスカブ | トリアゾール誘導体、及びそのニコチン性アセチルコリン受容体モジュレーターとしての使用 |
AR073501A1 (es) | 2008-09-08 | 2010-11-10 | Boehringer Ingelheim Int | Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa |
EP2350052B1 (en) * | 2008-09-29 | 2014-08-13 | Boehringer Ingelheim International GmbH | Antiproliferative compounds |
US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
US9063126B2 (en) | 2008-09-29 | 2015-06-23 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
US20110294668A1 (en) | 2008-12-08 | 2011-12-01 | North Carolina State University | Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives |
WO2010094695A1 (en) | 2009-02-17 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases |
WO2010144686A1 (en) | 2009-06-10 | 2010-12-16 | North Carolina State University | Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives |
WO2011008312A2 (en) | 2009-07-14 | 2011-01-20 | Abbott Laboratories | Indole and indoline derivatives and methods of use thereof |
CA2782361C (en) | 2009-12-17 | 2018-01-16 | Abbott Laboratories | Bridgehead amine ring-fused indoles and indolines useful to treat neurodegenerative and neuropsychiatric disorders |
WO2011084433A2 (en) | 2009-12-17 | 2011-07-14 | Abbott Laboratories | Aza-bridged ring-fused indoles and indolines |
US8809532B2 (en) | 2009-12-17 | 2014-08-19 | Abbvie Inc. | Aza-ring fused indole and indoline derivatives |
US9174949B2 (en) | 2010-01-07 | 2015-11-03 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
WO2011085261A1 (en) * | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
EP2552905B1 (en) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | B-Raf kinase inhibitors |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
WO2012067822A1 (en) | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators |
US8466181B2 (en) * | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
WO2012101263A1 (en) * | 2011-01-28 | 2012-08-02 | 4Sc Discovery Gmbh | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation |
BR112013019011B1 (pt) * | 2011-01-28 | 2021-10-13 | 4Sc Discovery Gmbh | Inibidores de il17 e ifn-gama, e seu uso |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
US8859549B2 (en) | 2011-05-13 | 2014-10-14 | Abbvie, Inc. | Potassium channel modulators |
WO2013018695A1 (ja) | 2011-07-29 | 2013-02-07 | 武田薬品工業株式会社 | 複素環化合物 |
US9447099B2 (en) * | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
WO2015067648A1 (de) * | 2013-11-05 | 2015-05-14 | Bayer Cropscience Ag | Neue verbindungen zur bekämpfung von arthropoden |
EP3394059B1 (en) | 2015-12-23 | 2020-11-25 | Chiesi Farmaceutici S.p.A. | 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
JP2020514323A (ja) | 2017-02-06 | 2020-05-21 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物と方法 |
CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
EP3759095A1 (en) | 2018-03-01 | 2021-01-06 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
WO2020007729A1 (en) * | 2018-07-04 | 2020-01-09 | Boehringer Ingelheim International Gmbh | Triazole benzamide derivatives as gpr142 agonists |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
AU2020328025A1 (en) | 2019-08-14 | 2022-03-03 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
KR20220099970A (ko) | 2019-10-11 | 2022-07-14 | 인사이트 코포레이션 | Cdk2 억제제로서의 이환식 아민 |
WO2022188792A1 (zh) * | 2021-03-12 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
KR20240107099A (ko) | 2021-11-19 | 2024-07-08 | 닛뽕소다 가부시키가이샤 | 2-알킬싸이오-1-이미다조일에타논 화합물의 제조 방법 |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
JP3418624B2 (ja) | 1996-06-10 | 2003-06-23 | メルク エンド カンパニー インコーポレーテッド | サイトカイン阻害活性を有する置換イミダゾール類 |
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
JP4385414B2 (ja) * | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
CA2327185A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
US6506747B1 (en) | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
JP2002527134A (ja) | 1998-10-13 | 2002-08-27 | ソマネティクス コーポレイション | 多チャンネル無侵襲組織オキシメータ |
ES2200566T3 (es) | 1998-10-23 | 2004-03-01 | Dow Agrosciences Llc | 3-(piridilo sustituido)-1,2,4-triazoles insecticidas. |
US6451820B1 (en) * | 2000-03-23 | 2002-09-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents |
US6498423B1 (en) | 2001-06-27 | 2002-12-24 | Welch Allyn, Inc. | Lamp thermal control by directed air flow |
US7297708B2 (en) | 2001-09-06 | 2007-11-20 | Bristol-Myers Squibb Company | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands |
ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
PL1618092T3 (pl) | 2003-05-01 | 2011-02-28 | Bristol Myers Squibb Co | Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy |
-
2005
- 2005-03-04 DE DE602005014621T patent/DE602005014621D1/de active Active
- 2005-03-04 EP EP05724523A patent/EP1725544B1/en active Active
- 2005-03-04 JP JP2007502866A patent/JP4850824B2/ja active Active
- 2005-03-04 ES ES05724523T patent/ES2327940T3/es active Active
- 2005-03-04 RS RSP-2009/0256A patent/RS50796B/sr unknown
- 2005-03-04 CA CA2557856A patent/CA2557856C/en not_active Expired - Fee Related
- 2005-03-04 BR BRPI0508561-6A patent/BRPI0508561A/pt not_active IP Right Cessation
- 2005-03-04 KR KR1020067020618A patent/KR20060129077A/ko not_active Application Discontinuation
- 2005-03-04 NZ NZ550148A patent/NZ550148A/en unknown
- 2005-03-04 AU AU2005223738A patent/AU2005223738B2/en not_active Ceased
- 2005-03-04 EP EP07112458A patent/EP1887003A1/en not_active Withdrawn
- 2005-03-04 EA EA200601571A patent/EA011634B1/ru not_active IP Right Cessation
- 2005-03-04 AT AT05724523T patent/ATE432273T1/de active
- 2005-03-04 PT PT05724523T patent/PT1725544E/pt unknown
- 2005-03-04 SI SI200530754T patent/SI1725544T1/sl unknown
- 2005-03-04 WO PCT/US2005/006997 patent/WO2005090333A1/en active Application Filing
- 2005-03-04 UA UAA200610490A patent/UA85702C2/ru unknown
- 2005-03-04 DK DK05724523T patent/DK1725544T3/da active
- 2005-03-04 PL PL05724523T patent/PL1725544T3/pl unknown
- 2005-03-04 CN CNA2005800078734A patent/CN1930144A/zh active Pending
- 2005-03-07 PE PE2005000254A patent/PE20051146A1/es not_active Application Discontinuation
- 2005-03-07 US US11/074,354 patent/US7214802B2/en active Active
- 2005-03-07 MY MYPI20050920A patent/MY143000A/en unknown
- 2005-03-08 TW TW094106994A patent/TW200602313A/zh unknown
- 2005-03-09 AR ARP050100899A patent/AR048315A1/es active Pending
-
2006
- 2006-07-26 ZA ZA200606177A patent/ZA200606177B/xx unknown
- 2006-09-07 IL IL177937A patent/IL177937A0/en unknown
- 2006-09-08 EC EC2006006833A patent/ECSP066833A/es unknown
- 2006-09-13 NO NO20064120A patent/NO20064120L/no not_active Application Discontinuation
-
2007
- 2007-01-30 US US11/668,704 patent/US7514458B2/en active Active
-
2009
- 2009-06-24 HR HR20090334T patent/HRP20090334T1/xx unknown
- 2009-08-24 CY CY20091100893T patent/CY1109333T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
AR054799A1 (es) | Derivados de oxindol | |
AR058703A1 (es) | Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
PE20081448A1 (es) | Inhibidores de transcriptasa inversa no nucleosidicos | |
AR078786A1 (es) | Derivados de la cromenona | |
AR023703A1 (es) | N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa | |
PE20060775A1 (es) | Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa | |
NO20062894L (no) | 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer | |
AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
AR050430A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |